HealthInvest Partners AB grew its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 18.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 326,840 shares of the biopharmaceutical company's stock after purchasing an additional 51,368 shares during the quarter. Amicus Therapeutics comprises 1.4% of HealthInvest Partners AB's portfolio, making the stock its 22nd biggest holding. HealthInvest Partners AB owned approximately 0.11% of Amicus Therapeutics worth $3,076,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Y Intercept Hong Kong Ltd grew its position in Amicus Therapeutics by 245.5% during the fourth quarter. Y Intercept Hong Kong Ltd now owns 120,958 shares of the biopharmaceutical company's stock worth $1,139,000 after buying an additional 85,951 shares in the last quarter. Transcend Capital Advisors LLC grew its position in Amicus Therapeutics by 11.3% during the fourth quarter. Transcend Capital Advisors LLC now owns 363,913 shares of the biopharmaceutical company's stock worth $3,428,000 after buying an additional 37,059 shares in the last quarter. Legacy Capital Group California Inc. grew its position in Amicus Therapeutics by 20.2% during the fourth quarter. Legacy Capital Group California Inc. now owns 23,229 shares of the biopharmaceutical company's stock worth $219,000 after buying an additional 3,900 shares in the last quarter. New York State Common Retirement Fund grew its position in Amicus Therapeutics by 2.8% during the fourth quarter. New York State Common Retirement Fund now owns 943,114 shares of the biopharmaceutical company's stock worth $8,884,000 after buying an additional 25,600 shares in the last quarter. Finally, Rice Hall James & Associates LLC grew its position in Amicus Therapeutics by 41.0% during the fourth quarter. Rice Hall James & Associates LLC now owns 1,371,080 shares of the biopharmaceutical company's stock worth $12,916,000 after buying an additional 398,942 shares in the last quarter.
Insiders Place Their Bets
In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company's stock, valued at approximately $8,884,273.08. The trade was a 0.84 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.20% of the company's stock.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on FOLD. Guggenheim raised their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. raised their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 12th. Wells Fargo & Company cut their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, February 20th. StockNews.com cut shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.75.
Read Our Latest Research Report on FOLD
Amicus Therapeutics Price Performance
Shares of Amicus Therapeutics stock traded up $0.16 during midday trading on Thursday, reaching $9.19. The company had a trading volume of 2,374,516 shares, compared to its average volume of 2,312,279. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The company has a market capitalization of $2.82 billion, a price-to-earnings ratio of -51.06, a price-to-earnings-growth ratio of 1.51 and a beta of 0.61. The stock has a fifty day simple moving average of $9.51 and a 200 day simple moving average of $10.37. Amicus Therapeutics, Inc. has a 1-year low of $8.78 and a 1-year high of $13.80.
About Amicus Therapeutics
(
Free Report)
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Further Reading
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
